Variable Access to Clopidogrel in a Harmonized EU Market

Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
Value in Health (Impact Factor: 3.28). 06/2008; 11(5):989-95. DOI: 10.1111/j.1524-4733.2008.00331.x
Source: PubMed


This study focuses on the different national coverage and reimbursement strategies and their consequences for access to clopidogrel, a drug with a central European Union (EU) registration. Our objectives are 1) to assess whether changes in reimbursement policies in EU member states influenced clopidogrel prescribing; and 2) to determine whether clopidogrel-specific policy characteristics, general characteristics of the health system, or indicators for the amount of cardiovascular care delivered were associated with the level of clopidogrel prescribing.
Data were collected in Austria, Belgium, Denmark, Germany, Hungary, Portugal, Slovenia, The Netherlands, and the United Kingdom (England). Utilization rates were expressed as defined daily doses (DDDs)/1000 persons/day. To determine whether changes in reimbursement policies influenced clopidogrel utilization, a segmented linear regression approach was used.
Clopidogrel prescribing varied widely in the studied countries, from 2.76 (The Netherlands) to 6.83 (Belgium) DDDs/1000 persons/day (March 2005). Six countries had therapeutic indication restrictions to clopidogrel use. Health system characteristics did not explain variation in clopidogrel prescribing.
A disconnect will be indicated in this study between the concept of a harmonized EU pharmaceuticals market and the reality in an individual member state. Although clopidogrel was centrally registered in the EU, policy measures at the national level result in different roles in clinical practice for this drug.

Download full-text


Available from: Eibert R Heerdink, Oct 16, 2014
  • Source
    • "Western European health care systems aim to achieve optimal health and economic outcomes for society as a whole as well as for the individual patient. Governments strive to ensure affordable access to a wide range of prescription medicines equitably across all areas and to all patients [8]. However, individual governments may take different measures to achieve this goal, which may result in variable access to these biologicals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors used in the treatment of rheumatoid arthritis as a measure of access to treatment with new medicines. In addition, characteristics both related to national health systems and spending will be assessed to explore possible differences in international utilisation. Data from four European countries were included: Ireland, The Netherlands, Norway and Portugal. Annual utilisation rates of TNFalpha inhibitors (2003-2007) were expressed as defined daily doses (DDDs)/1000 inhabitants/day. Qualitative data such as country characteristics, national health policy characteristics, guidelines were obtained from the literature. In addition, interviews were held with leading rheumatologists of each country to put obtained results into (cultural) context. Utilisation of TNFalpha inhibitors varied widely from 0.32 (Portugal) to 1.89 (Norway) DDDs/1000 inhabitants/day (2007). A major driver for the utilisation of TNFalpha inhibitors seemed to be the country's total health expenditure (R(2)=0.81). When the use of TNFalpha inhibitors became more established, the association seemed stronger. Differences in health expenditure were nevertheless not the only determinant of usage. Cultural aspects such as difference in recognition of guidelines also come into play when looking at differences in TNFalpha utilisation between countries. The prospects of patients receiving TNFalpha inhibitor treatment depend on the country where they are living. In case uniformity of management and treatment would be considered to provide health benefits, the extent and the causes of variation should feature prominently on future public health agendas.
    Full-text · Article · Nov 2011 · Health Policy
  • [Show abstract] [Hide abstract]
    ABSTRACT: A neurophysiological follow-up (EEG, exogeneous and endogeneous evoked potentials - EP) was performed over a 4-month period in a patient who presented a long-lasting coma following a cardiac arrest and an amniotic embolism. A pure anoxic aetiology was ruled out starting from the second day on the basis of a dissociation between mildly altered flash visual EP and markedly altered somatosensory EP, indicating focal brain-stem pathology. Endogeneous EP reappeared after 12 days. This patient recovered consciousness after 51 days. Despite the absence of MM abnormalities, we put forward the hypothesis that a brain-stem embolism had, in fact, worsened the clinical picture of an actually moderate anoxia. This case exemplifies the interest of an integrated neurophysiological approach (EEG, exogeneous three-modality EP and endogeneous EP) in the early evaluation of coma. It also illustrates the complement between structural imaging and functional assessment of the nervous system.
    No preview · Article · Sep 1998 · Neurophysiologie Clinique/Clinical Neurophysiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is little empirical information about the role of new chemical entities (NCEs) and to what extent they are being adopted in modern health care. We aimed to investigate which NCEs were launched in Finland during the years 1996 through 2005 and how they penetrated the market in Finland. NCEs were identified from Finnish drug compendiums and verified from marketing authorization and drug wholesale databases. Market penetration was determined by extracting data about outpatient drug costs and consumption in the year 2005 from drug wholesale databases. Of the 294 NCEs introduced in 1996 through 2005, 55% were authorized nationally and 45% by the European Commission. Two hundred two NCEs (69%) had pharmacy sales in 2005. Most NCEs were for cancer (19), infections (18), cardiovascular diseases (17), and pain and arthritis (14). NCEs introduced from 1996 through 2005 comprised 38% of total outpatient prescription drug costs and 19% of the total volume of NCEs used by outpatients in 2005. The corresponding figures for the NCEs introduced in 2001 through 2005 were 11% and 4%. All drugs for dementia and multiple sclerosis, all biological drugs for rheumatoid arthritis, and most drugs for erectile dysfunction and osteoporosis were introduced during the study period. The cost of NCEs also accounted for >50% of costs for drugs to treat hyperlipidemia, peptic ulcer, psychosis, and diabetes mellitus. The use of NCEs was greater when measured in monetary value than in volume. The overall costs of NCEs introduced from 1996 through 2005 were high in several major drug classes, although their share of overall use was modest when measured in volume. The market penetration of drugs introduced during 2001 through 2005 was still rather low in 2005.
    No preview · Article · Mar 2009 · Clinical Therapeutics
Show more